DLBCL

Laurie Sehn | ASCO 2018 | Polatuzumab vedotin, bendamustine and rituximab combination for R/R DLBCL

L:

ASCO Annual Meeting, 1-5 June 2018, Chicago, IL

Laurie Sehn
British Columbia Cancer, Vancouver, CN

Interview topic: Polatuzumab vedotin, bendamustine and rituximab combination for R/R DLBCL

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF